Angioedema due to acquired C1-inhibitor deficiency: A bridging condition between autoimmunity and lymphoproliferation

Massimo Cugno, Roberto Castelli, Marco Cicardi

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Angioedema due to an acquired deficiency in the inhibitor of the first component of human complement (CI-INH) is a rare syndrome that is usually identified as acquired angioedema (AAE). The clinical features of C1-INH deficiency, which may also be of genetic origin (hereditary angioedema, HAE), include subcutaneous, non-pruritic swelling, involvement of the upper respiratory tract, and abdominal pain due to partial obstruction of the gastrointestinal tract. Unlike those with HAE, AAE patients have no family history of angioedema and are characterised by the late onset of symptoms and various responses to treatment due to the hypercatabolism of C1-INH. The reduction in C1-INH function leads to activation of the classical complement pathway and complement consumption, as well as activation of the contact system leading to the generation of the vasoactive peptide bradykinin, increased vascular permeability, and angioedema. AAE is frequently associated with lymphoproliferative diseases ranging from monoclonal gammopathies of uncertain significance (MGUS) to non-Hodgkin's lymphoma (NHL) and/or anti-C1-INH inactivating autoantibodies. The coexistence of true B cell malignancy, non-malignant B cell proliferation and pathogenic autoimmune responses suggests that AAE patients are all affected by altered B cell proliferation control although their clinical evolution may vary.

Original languageEnglish
Pages (from-to)156-159
Number of pages4
JournalAutoimmunity Reviews
Volume8
Issue number2
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Hereditary Angioedemas
Angioedema
Autoimmunity
B-Lymphocytes
Cell Proliferation
Classical Complement Pathway
Paraproteinemias
Capillary Permeability
Bradykinin
Respiratory System
Autoantibodies
Non-Hodgkin's Lymphoma
Abdominal Pain
Gastrointestinal Tract
Peptides
Acquired angioedema
Neoplasms

Keywords

  • Acquired C1 inhibitor deficiency
  • Autoantibodies
  • Complement
  • Lymphoproliferative disease

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Angioedema due to acquired C1-inhibitor deficiency : A bridging condition between autoimmunity and lymphoproliferation. / Cugno, Massimo; Castelli, Roberto; Cicardi, Marco.

In: Autoimmunity Reviews, Vol. 8, No. 2, 12.2008, p. 156-159.

Research output: Contribution to journalArticle

@article{0f8f41db05c44ace9d03ef6284f7cad1,
title = "Angioedema due to acquired C1-inhibitor deficiency: A bridging condition between autoimmunity and lymphoproliferation",
abstract = "Angioedema due to an acquired deficiency in the inhibitor of the first component of human complement (CI-INH) is a rare syndrome that is usually identified as acquired angioedema (AAE). The clinical features of C1-INH deficiency, which may also be of genetic origin (hereditary angioedema, HAE), include subcutaneous, non-pruritic swelling, involvement of the upper respiratory tract, and abdominal pain due to partial obstruction of the gastrointestinal tract. Unlike those with HAE, AAE patients have no family history of angioedema and are characterised by the late onset of symptoms and various responses to treatment due to the hypercatabolism of C1-INH. The reduction in C1-INH function leads to activation of the classical complement pathway and complement consumption, as well as activation of the contact system leading to the generation of the vasoactive peptide bradykinin, increased vascular permeability, and angioedema. AAE is frequently associated with lymphoproliferative diseases ranging from monoclonal gammopathies of uncertain significance (MGUS) to non-Hodgkin's lymphoma (NHL) and/or anti-C1-INH inactivating autoantibodies. The coexistence of true B cell malignancy, non-malignant B cell proliferation and pathogenic autoimmune responses suggests that AAE patients are all affected by altered B cell proliferation control although their clinical evolution may vary.",
keywords = "Acquired C1 inhibitor deficiency, Autoantibodies, Complement, Lymphoproliferative disease",
author = "Massimo Cugno and Roberto Castelli and Marco Cicardi",
year = "2008",
month = "12",
doi = "10.1016/j.autrev.2008.05.003",
language = "English",
volume = "8",
pages = "156--159",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Angioedema due to acquired C1-inhibitor deficiency

T2 - A bridging condition between autoimmunity and lymphoproliferation

AU - Cugno, Massimo

AU - Castelli, Roberto

AU - Cicardi, Marco

PY - 2008/12

Y1 - 2008/12

N2 - Angioedema due to an acquired deficiency in the inhibitor of the first component of human complement (CI-INH) is a rare syndrome that is usually identified as acquired angioedema (AAE). The clinical features of C1-INH deficiency, which may also be of genetic origin (hereditary angioedema, HAE), include subcutaneous, non-pruritic swelling, involvement of the upper respiratory tract, and abdominal pain due to partial obstruction of the gastrointestinal tract. Unlike those with HAE, AAE patients have no family history of angioedema and are characterised by the late onset of symptoms and various responses to treatment due to the hypercatabolism of C1-INH. The reduction in C1-INH function leads to activation of the classical complement pathway and complement consumption, as well as activation of the contact system leading to the generation of the vasoactive peptide bradykinin, increased vascular permeability, and angioedema. AAE is frequently associated with lymphoproliferative diseases ranging from monoclonal gammopathies of uncertain significance (MGUS) to non-Hodgkin's lymphoma (NHL) and/or anti-C1-INH inactivating autoantibodies. The coexistence of true B cell malignancy, non-malignant B cell proliferation and pathogenic autoimmune responses suggests that AAE patients are all affected by altered B cell proliferation control although their clinical evolution may vary.

AB - Angioedema due to an acquired deficiency in the inhibitor of the first component of human complement (CI-INH) is a rare syndrome that is usually identified as acquired angioedema (AAE). The clinical features of C1-INH deficiency, which may also be of genetic origin (hereditary angioedema, HAE), include subcutaneous, non-pruritic swelling, involvement of the upper respiratory tract, and abdominal pain due to partial obstruction of the gastrointestinal tract. Unlike those with HAE, AAE patients have no family history of angioedema and are characterised by the late onset of symptoms and various responses to treatment due to the hypercatabolism of C1-INH. The reduction in C1-INH function leads to activation of the classical complement pathway and complement consumption, as well as activation of the contact system leading to the generation of the vasoactive peptide bradykinin, increased vascular permeability, and angioedema. AAE is frequently associated with lymphoproliferative diseases ranging from monoclonal gammopathies of uncertain significance (MGUS) to non-Hodgkin's lymphoma (NHL) and/or anti-C1-INH inactivating autoantibodies. The coexistence of true B cell malignancy, non-malignant B cell proliferation and pathogenic autoimmune responses suggests that AAE patients are all affected by altered B cell proliferation control although their clinical evolution may vary.

KW - Acquired C1 inhibitor deficiency

KW - Autoantibodies

KW - Complement

KW - Lymphoproliferative disease

UR - http://www.scopus.com/inward/record.url?scp=56349101289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56349101289&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2008.05.003

DO - 10.1016/j.autrev.2008.05.003

M3 - Article

C2 - 19014872

AN - SCOPUS:56349101289

VL - 8

SP - 156

EP - 159

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 2

ER -